Beam Therapeutics Stock Forecast

Stock Price Forecast

According to 17 analysts polled by S&P Global, Beam Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $51.07. The average 1-year stock price forecast is 74.24% higher than the current stock price, while the lowest is $26 (-11.29%) and the highest is $80 (+172.94%).

Price Target: $51.07 (+74.24%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$26	$51.07	$47	$80
Change	-11.29%	+74.24%	+60.35%	+172.94%

Analyst Ratings

The average analyst rating for Beam Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	13	13	14	14	14	14
Buy	1	1	1	1	1	1
Hold	2	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	16	16	17	17	17	17

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Buy Maintains $75	Buy	Maintains	$75	+155.89%	May 21, 2026
Patrick Trucchio H.C. Wainwright	H.C. Wainwright	Buy Reiterates $80	Buy	Reiterates	$80	+172.94%	May 21, 2026
Samantha Semenkow Citi	Citi	Buy Maintains $68	Buy	Maintains	$68	+132.00%	May 14, 2026
William Pickering Bernstein	Bernstein	Buy Reiterates $40 → $39	Buy	Reiterates	$40 → $39	+33.06%	May 13, 2026
Alec Stranahan Bank of America Securities	Bank of America Securities	Buy Reiterates $47	Buy	Reiterates	$47	+60.35%	May 13, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

73.19M

from 139.74M

-47.63%

from 139.74M

Revenue Next Year

87.27M

from 73.19M

19.25%

from 73.19M

EPS This Year

-4.47

from -0.81

EPS Next Year

-4.74

from -4.47

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	51.84M	60.92M	377.71M	63.52M	139.74M	73.19M
Revenue Growth	215,916.67%	17.51%	520.01%	-83.18%	120.01%	-47.63%
Gross Profit	-180.29M	-250.67M	-59.67M	-304.04M	-269.88M	73.19M
Gross Margin	-347.75%	-411.48%	-15.80%	-478.67%	-193.12%	100.00%
Operating Income	-237.51M	-338.48M	-176.49M	-415.57M	-383.69M	-499.51M
Net Income	-370.64M	-289.09M	-132.53M	-376.74M	-79.99M	-464.78M
EPS	-	-	-	-	-0.81	-4.47
Free Cash Flow	-335.34M	138.32M	-50.36M	-156.52M	-220.31M	-423.90M
No. Analysts	-	-	-	-	-	15

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	136.8M
Avg	73.2M
Low	35.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-2.1%
Avg	-47.6%
Low	-75.0%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-4.47
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-